A comprehensive view of Neurological/Cognitive Health. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Clinical-stage drug development firm Cerevance announces multi-year research collaboration with Merck; firms to use Cerevance’s proprietary nuclear enriched transcript sorting sequence to identify novel targets for Alzheimer’s disease
Published: August 15, 2022 by Marketline - Deals
In the migraine treatment drug market, Q2 sales of Lilly’s Emgality hit US$157.5M, AbbVies’s Ubrelvy sales total US$138.0M, Biohaven’s Nurtec has US$123.6M in sales; Amgen’s Aimovig records US$92.0M in sales in Q2
Published: August 09, 2022 by FiercePharma
Biogen’s staff count at Cambridge, Massachusetts, site drops by 301 employees since first of the year reports Boston Business Journal; Biogen to lay off as many as 1,000 employees in US$1B cost-cutting plan due to failure of Aduhelm Alzheimer’s drug
Published: August 08, 2022 by FiercePharma
FDA starts priority review of Eli Lilly’s donanemab injectable Alzheimer drug designed to clear amyloid plaque from brain; late-stage study results expected by middle of 2023
Published: August 08, 2022 by SeeNews Pharmaceuticals
Boston Scientific to pay Nevro Corp. US$85.0M to settle intellectual property litigation; Boston Scientific and Nevro free to continue using features, capabilities embodied in their current spinal cord stimulation technology products
Published: August 03, 2022 by SeeNews Pharmaceuticals

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count